Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Adding Immix Biopharma (IMMX) to 2022 Biotech 12 Pack List.
Added to 12 Biotech Stocks we Expect to Double List.
The Original Biotech 6-Pack from 2020, is Growing to...
Institutional Analyst Newsletter. April 14, 2022.
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict
LIVE QUOTE
Provention Biosciences (PRVB) Enters the Danger Zone.
Chart Looks Beautiful - But Nervous is why, we use soft and dry.
LIVE QUOTE
We'll...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Adding Ardelyx (ARDX) $1.57 to Watch List.
FDA Advisory Committee Says Go Forth Young Man!
While we hadn't previously owned Ardelyx, nor are they a...
ImmixBio (IMMX) Announces Positive Clinical Trial Safety Data.
Demonstrates 100% Completion of Planned Treatment Cycles.
Immix Biopharma, Inc. Wed, January 19, 2022.
ImmixBio...
Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is our 'stocks we hope to double' Watch List.
LIVE QUOTE
FDA Approval for Provention Bio (PRVB).
Re-cork the Champagne!
We were contemplating (dreaming) about an opening price over $12, and then a drift up...